-
As you check the chart of a new patient, you note that she has previously experienced nausea on birth control pills, but cant remember the brand name of her prescribed oral contraceptive (OC). She would like to re-establish pill use. Which OC will you suggest?
-
On Aug. 26, the U.S. Food and Drug Administration (FDA) announced that it would indefinitely postpone its decision to allow nonprescription status for the emergency contraceptive pill Plan B popularly known as the morning-after pill.
-
As you review the list of contraceptive options available at your family planning facility with your next female patient, which one most likely will receive the nod from her?
-
More women are choosing long-term birth control through use of intrauterine contraception, say participants in the 2005 Contraceptive Technology Update Contraception Survey.
-
Rewind to November 2004: the Food and Drug Administration (FDA) announces the addition of a black box warning to the labeling for the injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera, Pfizer, New York City and MedroxyPROGESTERone Injection, Teva Pharmaceuticals USA, North Wales, PA).
-
Although persons who work rotating shifts not uncommonly experience transient sleep disturbances, in some individuals who maintain a night-shift jobs, sleep disturbances are persistent and may be accompanied by sleepiness at work.
-
The prevalence of depression among low-income, ethnic minority women with breast or gynecologic cancer is largely unknown, but limited formal screening programs and restricted access to effective therapies would suggest the number to be high.
-
The Safety of Estrogens in Lupus Erythematosus, National Assessment (SELENA) was composed of 2 randomized, placebo-controlled, multicenter trialsone with estrogen-progestin therapy in postmenopausal women and one comparing oral contraceptives and placebo.
-
The Danish Nurse Cohort was established in 1993. A total 10,874 women were available for follow-up after excluding hysterectomized women and cases of breast cancer identified at baseline.
-
Lacey and colleagues from the National Cancer Institute report the risks of endometrial cancer in users of combined estrogen-progestin regimens.
